SpecificationsOrganism/cell line/tissue*Homo Sapiens*SexMaleSequencer or array typeIllumina Hiseq 2000 genome analyzerData formatRaw: SRA study; processed: BEDExperimental factorsNormal, primary and therapy resistant tumors, lymph node metastasesExperimental featuresFAIRE-seq and Androgen Receptor ChIP-seqConsentLeftover anonymized tissue (not traceable back to the patient and not interfering with care and/or prognosis) used for research purposes.Sample source locationSamples were from prostate cancer patients, treated at the Erasmus University Medical Center (EMC; Rotterdam, The Netherlands), The Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (Amsterdam, The Netherlands)

**Direct link to deposited data** <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65478>

1. Experimental design, materials and methods {#s0005}
=============================================

1.1. Clinical samples and experimental design {#s0010}
---------------------------------------------

Fresh frozen tissue samples were obtained through postoperative needle biopsies targeting both tumor and normal areas of prostatectomy specimens at The Netherlands Cancer Institute (Amsterdam, The Netherlands). Tissue samples from androgen deprivation resistant tumors (from transurethral resection of the prostate (TURP)) and lymph node metastases were obtained from the Erasmus University Medical Center (Rotterdam, The Netherlands). Slides stained with hematoxylin and eosin (H&E) of the cases were reviewed by our pathologists. Clinical and pathological parameters of the selected patients are provided in [Table 1](#t0005){ref-type="table"}. Leftover anonymized tissue, which cannot be traced back to the patient and does not interfere with care and/or prognosis, and would have been discarded otherwise, has been used in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in The Netherlands. NKI and Erasmus MC institutional medical ethics committees have approved the study.

FAIRE-seq was performed on four normal samples, four primary, three therapy resistant tumors and three lymph node metastases ([Fig. 1](#f0005){ref-type="fig"}). Androgen Receptor ChIP-seq was carried out on four primary and three resistant tumors ([Fig. 1](#f0005){ref-type="fig"}).

1.2. Formaldehyde-assisted isolation of regulatory elements (FAIRE) {#s0015}
-------------------------------------------------------------------

FAIRE was performed as previously described [@bb0010]. Briefly, fresh frozen tissues were cross-linked with 1% formaldehyde for 20 min. After washing, nuclei were isolated as described before [@bb0015]. Afterwards chromatin was sonicated, cleared by centrifugation and subjected to three consecutive phenol--chloroform--isoamyl alcohol (25:24:1) extractions. Reverse cross-linking was performed at 65 °C overnight. Subsequently, samples were treated with RNase A and proteinase K and purified by using a PCR purification kit (Roche).

1.3. Chromatin immunoprecipitation (ChIP) {#s0020}
-----------------------------------------

Chromatin immunoprecipitation was carried out as described before [@bb0015], [@bb0020]. 10 μg of AR-N20 (sc-618; Santa Cruz) antibody was used for immunoprecipitation, with 100 μl of Protein A magnetic beads (Invitrogen).

1.4. DNA sequencing {#s0025}
-------------------

Libraries were prepared according to Illumina DNA Sample Kit instructions. Sequencing was performed on the Illumina HiSeq 2000 Genome Analyzer using 51-bp reads. Reads were aligned to the Human Reference Genome (assembly hg19, February 2009) using bwa 0.5.9.

1.5. Data analysis {#s0030}
------------------

Reads that map uniquely to the genome, with MAPQ quality score above 20, were used for the analysis. FAIRE-seq and ChIP-seq peaks were called with two algorithms, MACS 1.4 [@bb0025] and DFilter 1.0 [@bb0030], against mixed input controls corresponding to each group. MACS was run with default parameters, except for p = 10^− 7^ for ChIP-seq data. DFilter was run with bs = 100, ks = 50 for FAIRE-seq data and bs = 50, ks = 30, refine, nonzero for ChIP-seq data. Peaks detected by both algorithms were used for further analysis. Sequencing read depths and number of called peaks can be found in [Table 2](#t0010){ref-type="table"}.

FAIRE-seq, ChIP-seq data and clinical annotation of the samples that are deposited in NCBI GEO under accession number [GSE65478](ncbi-geo:GSE65478){#ir0145}.

For further analysis, a merged list of peaks present in all samples from each technique was generated. The number of peaks detected by FAIRE-seq was 25,797, while 20,703 peaks were detected by ChIP-seq. The AR binding sites had a median width of 350 bp and peak size did not vary strongly with the largest peak size of 1202 bp ([Fig. 2](#f0010){ref-type="fig"}A). In contrast, FAIRE-seq peaks had a larger spread in size with a median size of 255 bp. The largest peak size of FAIRE-seq data was 2300 bp and a higher proportion of both small and large peaks was present ([Fig. 2](#f0010){ref-type="fig"}A). The distance to the nearest transcription start site (TSS) was determined by the GREAT tool (<http://great.stanford.edu>/) [@bb0035]. The number of peaks within 5 kb from the nearest TSS was significantly higher in FAIRE-seq data as compared to ChIP-seq data and the number of peaks further than 50 kb from a TSS was higher in ChIP-seq data than in FAIRE-seq (p \< 10^− 15^ Fisher\'s exact; [Fig. 2](#f0010){ref-type="fig"}B-C). This is in accordance with AR binding mainly distant enhancer elements [@bb0040], while accessible regions detected by FAIRE-seq include not only enhancers, but also promoters [@bb0045].

2. Conclusions {#s0035}
==============

In conclusion, we provide a unique dataset of genome-wide epigenetic profiling of prostate cancer tissue from different stages of the disease. The dataset consists of two parts: accessible chromatin profiling by FAIRE-seq and genome-wide androgen receptor binding to DNA by ChIP-seq. We previously used this dataset to identify changes in transcriptional regulation in prostate cancer upon acquisition of resistance to hormonal therapy, as well as to derive a prognostic gene expression signature for prostate cancer [@bb0005].
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![FAIRE-seq and ChIP-seq analyses were performed on normal prostate tissue and prostate cancer samples from different stages of the disease.](gr1){#f0005}

![Comparative analysis of FAIRE-seq and Androgen Receptor ChIP-seq data. (A) Size distribution of peaks detected by FAIRE-seq and ChIP-seq in prostate cancer specimens. Pie charts showing the percentage of peaks in categories based on the distance to the nearest transcription start site (TSS) in FAIRE-seq (B) and ChIP-seq (C) data.](gr2){#f0010}

###### 

Patient and tumor characteristics of the selected samples.

  Characteristic                       Number of patients                            
  ------------------------------------ -------------------- ----------- ------------ -------------
  *Treatment type*                                                                   
  Untreated                            3                    4           0            2
  Bicalutamide/cyproteron acetate      1                    0           0            0
  Bicalutamide/LHRH analogue           0                    0           1            0
  Cyproteron acetate + LHRH analogue   0                    0           1            0
  LHRH analogue                        0                    0           2            0
  LHRH analogue/Cyproteron Acetate     0                    0           0            1
                                                                                     
  *Gleason score*                                                                    
  6                                    1                    0           0            0
  7                                    2                    2           0            0
  8                                    0                    0           1            1
  9                                    1                    2           0            0
  10                                   0                    0           3            2
                                                                                     
  *Initial PSA (ng/ml)*                                                              
  Mean                                 8.7                  19.6        149.5        135.5
  Range                                5.3--13.0            8.5--38.0   6.5--511.0   17.0--254.0

###### 

Sequencing and peak calling details.

  GEO accession                                Experiment    Tissue       Total number of reads   Mapped reads   \% mapped reads   No. peaks
  -------------------------------------------- ------------- ------------ ----------------------- -------------- ----------------- -----------
  [GSM1598204](ncbi-geo:GSM1598204){#ir0005}   FAIRE-seq     Normal       19,147,127              17,986,187     93.94             50
  [GSM1598205](ncbi-geo:GSM1598205){#ir0010}   FAIRE-seq     Normal       21,599,945              19,883,501     92.05             472
  [GSM1598206](ncbi-geo:GSM1598206){#ir0015}   FAIRE-seq     Normal       26,080,719              25,043,481     96.02             61
  [GSM1598207](ncbi-geo:GSM1598207){#ir0020}   FAIRE-seq     Normal       23,167,347              22,177,458     95.73             2837
  [GSM1598208](ncbi-geo:GSM1598208){#ir0025}   FAIRE-seq     Primary      36,827,373              34,441,896     93.52             6450
  [GSM1598209](ncbi-geo:GSM1598209){#ir0030}   FAIRE-seq     Primary      18,306,926              17,002,416     92.87             1579
  [GSM1598210](ncbi-geo:GSM1598210){#ir0035}   FAIRE-seq     Primary      32,197,589              30,568,523     94.94             13,348
  [GSM1598211](ncbi-geo:GSM1598211){#ir0040}   FAIRE-seq     Primary      28,992,853              27,590,961     95.16             2243
  [GSM1598212](ncbi-geo:GSM1598212){#ir0045}   FAIRE-seq     Resistant    37,452,682              35,655,681     95.2              80
  [GSM1598213](ncbi-geo:GSM1598213){#ir0050}   FAIRE-seq     Resistant    28,372,546              26,836,918     94.59             3497
  [GSM1598214](ncbi-geo:GSM1598214){#ir0055}   FAIRE-seq     Resistant    27,545,618              26,061,843     94.61             5754
  [GSM1598215](ncbi-geo:GSM1598215){#ir0060}   FAIRE-seq     Metastasis   39,562,972              37,594,752     95.03             2043
  [GSM1598216](ncbi-geo:GSM1598216){#ir0065}   FAIRE-seq     Metastasis   29,130,845              27,291,106     93.68             281
  [GSM1598217](ncbi-geo:GSM1598217){#ir0070}   FAIRE-seq     Metastasis   27,253,810              25,789,354     94.63             1313
  [GSM1598218](ncbi-geo:GSM1598218){#ir0075}   AR ChIP-seq   Primary      13,782,549              12,232,556     88.75             754
  [GSM1598219](ncbi-geo:GSM1598219){#ir0080}   AR ChIP-seq   Primary      18,146,927              16,009,388     88.22             402
  [GSM1598220](ncbi-geo:GSM1598220){#ir0085}   AR ChIP-seq   Primary      13,040,014              11,254,994     86.31             17,511
  [GSM1598221](ncbi-geo:GSM1598221){#ir0090}   AR ChIP-seq   Primary      9,928,626               7,080,840      71.32             3278
  [GSM1598222](ncbi-geo:GSM1598222){#ir0095}   AR ChIP-seq   Primary      12,243,485              11,160,623     91.16             7932
  [GSM1598223](ncbi-geo:GSM1598223){#ir0100}   AR ChIP-seq   Resistant    16,518,987              14,727,645     89.16             739
  [GSM1598224](ncbi-geo:GSM1598224){#ir0105}   AR ChIP-seq   Resistant    16,382,421              14,441,817     88.15             238
  [GSM1598225](ncbi-geo:GSM1598225){#ir0110}   AR ChIP-seq   Resistant    15,621,538              13,967,477     89.41             1779
  [GSM1598226](ncbi-geo:GSM1598226){#ir0115}   Input         Resistant    28,171,838              26,825,849     95.22             
  [GSM1598227](ncbi-geo:GSM1598227){#ir0120}   Input         Metastasis   24,117,145              22,902,755     94.96             
  [GSM1598228](ncbi-geo:GSM1598228){#ir0125}   Input         Primary      23,982,305              22,739,491     94.82             
  [GSM1598229](ncbi-geo:GSM1598229){#ir0130}   Input         Primary      27,642,177              26,387,234     95.46             

[^1]: Equal contribution.
